Related Experiment Videos
Isolated lung perfusion for pulmonary metastases
Jeroen M H Hendriks1, Bart P Van Putte, Marco Grootenboers
1Department of Thoracic and Vascular Surgery, University Hospital Antwerp, Wilrijkstraat 10 B-2650, Edegem, Belgium. jeroen.hendriks@uza.be
Thoracic Surgery Clinics
|June 30, 2006
Summary
Isolated lung perfusion delivers high-dose chemotherapy for lung cancer survival. Clinical trials show this technique combined with surgery is feasible, but further research on regional perfusion is needed.
Area of Science:
- Surgical Oncology
- Pharmacology
- Thoracic Surgery
Background:
- Pulmonary metastasectomy aims to improve 5-year survival.
- Systemic chemotherapy has limitations in treating lung metastases.
- Isolated lung perfusion (ILP) is an experimental technique for targeted chemotherapy delivery.
Purpose of the Study:
- To evaluate isolated lung perfusion (ILP) for high-dose chemotherapy delivery.
- To assess the feasibility and safety of ILP in conjunction with pulmonary metastasectomy.
- To explore the potential of ILP to enhance survival rates after lung metastasis removal.
Main Methods:
- Experimental studies in animal models to assess pharmacokinetics and efficacy.
- Phase I clinical trials to determine maximum tolerated doses of chemotherapy agents.
- Investigating the combination of ILP with complete metastasectomy.
Main Results:
- Animal models showed ILP has superior pharmacokinetics and efficacy over systemic therapy.
- Phase I trials identified maximum tolerated doses for TNF-alpha, doxorubicin, cisplatin, and melphalan.
- Combining ILP with complete metastasectomy was found to be feasible in clinical trials.
Conclusions:
- Isolated lung perfusion is a promising technique for delivering high-dose chemotherapy to the lungs.
- The combination of ILP and complete pulmonary metastasectomy is feasible.
- Further investigation is required for combined isolated lung perfusion and regional lung perfusion techniques.